Navigation Links
Avandia May Slow Atherosclerosis After Bypass Surgery
Date:4/1/2008

But this new study of diabetes drug doesn't prove it's safe, critics say

TUESDAY, April 1 (HealthDay News) -- The controversial diabetes drug Avandia appears to slow the progression of atherosclerosis in diabetic patients who have undergone cardiac bypass surgery, thus protecting them from new cardiac problems, according to the results of a small study.

Avandia (rosiglitazone) has been associated with increased risk of heart attack and heart failure among patients receiving the drug. In November, the U.S. Food and Drug Administration, while calling the evidence for heart attack inconclusive, agreed to keep the drug on the market, but with a black box warning about the heart attack risk.

In the new study, which included almost 100 patients taking Avandia, the study authors said they found the drug was safe and had no more cardiovascular risks than a placebo.

The VICTORY (Vein Coronary Atherosclerosis and Rosiglitazone After Bypass Surgery) study included 193 patients with type 2 diabetes who had undergone cardiac bypass surgery. They were randomly assigned to receive Avandia or a placebo. The trial was paid for by GlaxoSmithKline, the maker of Avandia.

The researchers found that after one year, patients taking Avandia had better blood sugar control, compared with those on a placebo. In addition, patients taking Avandia showed improved cholesterol levels, fewer signs of inflammation of blood vessels, and lower blood pressure than those patients taking a dummy pill.

Also, there was no significant difference in cardiovascular events between the two groups, the researchers noted.

"The enrollment of high-risk cardiovascular patients with type 2 diabetes in a placebo-controlled trial with rosiglitazone was found to have an acceptable safety profile," the researchers concluded.

The findings were presented Tuesday at the American College of Cardiology annual meeting, in Chicago.
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Diabetes Drug Avandia Boosts Heart Risks: Study
2. GSK Revises US Labeling for Avandia(R)
3. Avandia Label to Get Heart-Attack Warning
4. Diabetes Drug Avandia Could Weaken Bones
5. Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
6. Older Diabetics Using Avandia Face Increased Death Risk
7. CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
8. Atherosclerosis solution is likely many years away
9. New potential drug target for the treatment of atherosclerosis
10. Study in Circulation Research details how diabetes drives atherosclerosis
11. Genes that protect against atherosclerosis identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... announce the development of it’s new program “Designing Secure Healthcare Systems” This ... engineers and technology leaders from healthcare organizations with access to the tactics, techniques ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... A ... emerged among U.S. emergency rooms in recent years, according to the American Dental Association. ... number of dental emergency visits went from 1.1 million in a single year to ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Illinois Health ... effective July 31. , The acquisition includes all of IBAM NA’s cyclotron sites ... to have both, a robust regionally located business, as well as a large manufacturing ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Constantin Vasilica, ... accompanied by tissue injury caused by diabetes after many years of suffering and using ... times, and he didn’t want to ask for extra time off or wait longer ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... medical information, risk management and investigative services, has introduced a new logo ... expert information solutions that improve business outcomes for its customers. EMSI’s new ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Partnerships at The Henry M. Jackson Foundation for the ... the recipients of the 2012 Heroes of Military Medicine ... selfless dedication to advancing medicine for our nation,s wounded, ... The recipients will be honored at the Heroes of ...
... Washington, D.C. People with schizophrenia report ... clinical program, according to results announced today from ... of Care for People with Schizophrenia , was ... Healthcare (National Council) and administered at 10 community ...
... TUESDAY, March 6 (HealthDay News) -- ,Hospitalizations from angiodema, ... skin often around the eyes and mouth, are on ... York Downtown Hospital searched a national database for hospitalizations ... fatal whole-body reaction) and angiodema. While hospitalization rates ...
... The American College of Physicians (ACP) today issued a ... is the second leading cause of cancer-related deaths for ... statement and a patient summary appear in the March ... published by ACP. ACP developed this guidance statement ...
... , MONDAY, March 5 (HealthDay News) -- Pregnant women taking ... reduced head growth, a new study suggests. The researchers ... as Paxil and Prozac relieved depression in these women, they ... birth. "Fetal body growth is a marker of fetal ...
... Jenifer Goodwin HealthDay Reporter , MONDAY, March ... or have other breathing issues while sleeping are more ... 7, new research suggests. Those issues can include ... depression, conduct problems such as rule-breaking and aggressiveness and ...
Cached Medicine News:Health News:HJF Center announces Heroes of Military Medicine award recipients 2Health News:Pilot program demonstrates measureable benefits for people with schizophrenia 2Health News:American College of Physicians releases new colorectal cancer screening guidance statement 2Health News:Moms' Antidepressants May Affect Babies' Head Size: Study 2Health News:Moms' Antidepressants May Affect Babies' Head Size: Study 3Health News:Snoring Tots May Develop Behavioral Issues Later 2Health News:Snoring Tots May Develop Behavioral Issues Later 3
(Date:8/3/2015)... , Aug. 3, 2015  BioElectronics Corporation (OTC Pink: ... management, announced that Andrew J. Whelan , President ... his program "On Business" at 9am EDT on Wednesday, ... live, tune to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... the exceptional acceptance the company,s flagship product, ActiPatch Therapy, ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, Inc., ... its second clinical development program with a Phase ... CL-H1T contains fast-dissolving promethazine and ... as a treatment for migraine headache pain and ... "Many patients with migraine headaches also suffer from ...
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... (Nasdaq: PRGO ; TASE) today announced that ... calcipotriene 0.005% and betamethasone dipropionate 0.064% ointment, a generic ... first to file on this product. Taclonex® ... treatment of psoriasis vulgaris in adults 18 years of ...
... NEW YORK, Feb. 22, 2011 Reportlinker.com announces ... in its catalogue: Global Pharmaceutical ... This report analyzes the worldwide ... by the following Dosage Forms: Injectables (Injections, Vials, ...
Cached Medicine Technology:Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 2Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma 3Reportlinker Adds Global Pharmaceutical Contract Manufacturing Industry 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: